S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models
- 609 Downloads
Serotonin (5-HT)2C receptors are implicated in the control of mood, and their blockade is of potential interest for the management of anxiodepressive states.
Herein, we characterized the in vitro and in vivo pharmacological profile of the novel benzourea derivative, S32006.
Materials and methods
Standard cellular, electrophysiological, neurochemical, and behavioral procedures were used.
S32006 displayed high affinity for human (h)5-HT2C and h5-HT2B receptors (pK is, 8.4 and 8.0, respectively). By contrast, it had negligible (100-fold lower) affinity for h5-HT2A receptors and all other sites examined. In measures of Gq-protein coupling/phospholipase C activation, S32006 displayed potent antagonist properties at h5-HT2C receptors (pK B values, 8.8/8.2) and h5-HT2B receptors (7.8/7.7). In vivo, S32006 dose-dependently (2.5–40.0 mg/kg, i.p. and p.o.) abolished the induction of penile erections and a discriminative stimulus by the 5-HT2C receptor agonist, Ro60,0175, in rats. It elevated dialysis levels of noradrenaline and dopamine in the frontal cortex of freely moving rats, and accelerated the firing rate of ventrotegmental dopaminergic and locus ceruleus adrenergic neurons. At similar doses, S32006 decreased immobility in a forced-swim test in rats, reduced the motor depression elicited by 5-HT2C and α2-adrenoceptor agonists, and inhibited both aggressive and marble-burying behavior in mice. Supporting antidepressant properties, chronic (2–5 weeks) administration of S32006 suppressed “anhedonia” in a chronic mild stress procedure and increased both expression of BDNF and cell proliferation in rat dentate gyrus. Finally, S32006 (0.63–40 mg/kg, i.p. and p.o) displayed anxiolytic properties in Vogel conflict and social interaction tests in rats.
S32006 is a potent 5-HT2C receptor antagonist, and possesses antidepressant and anxiolytic properties in diverse rodent models.
Keywords5-HT2C receptor Anxiolytic Antidepressant Stress Ventral tegmental area Locus ceruleus BDNF
We thank Manuelle Touzard, Sylvie Girardon, Sylvie Veiga, Huguette Gressier, Brigitte Denorme, Loretta Iob Laetitia Cistarelli, Rodolphe Billiras, and Jimmy Mullot for excellent technical assistance.
- Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4:399–408PubMedGoogle Scholar
- Bristow LJ, O’Connor D, Watts R, Duxon MS, Hutson PH (2000) Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY100,635, in the rat. Neuropsychopharmacology 39:1222–1236Google Scholar
- Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ (2008) Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-HT2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 73:748–757PubMedGoogle Scholar
- Cowen PJ (1998) Pharmacological challenge tests and brain serotonin function in depression during SSRI treatment. In: Briley M, Montgomery S (eds) Antidepressant therapy at the dawn of third millennium. Martin Dunitz Ltd, London, pp 175–189Google Scholar
- Cryan JF, Lucki I (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J Pharm Exp Ther 295:1120–1126Google Scholar
- Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ (2002) Differential activation of Gq/11 and Gi3 proteins as 5-hydroxytryptamine2C receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62:578–586PubMedGoogle Scholar
- De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O’Neill MJ, Zetterström TSC (2004) Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128:597–604PubMedGoogle Scholar
- Descamps-Lefebvre A, Rousset C, Millan MJ, Spedding M, Delagrange P, Cespuglio R (2008) Effects of agomelatine, a MT1/MT2 agonist and 5-HT2C antagonist, on 24-hour electroencephalogram in the rat. Soc Neurosci Abstr P501.17Google Scholar
- Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin2C/2B receptors enhances mesolimbic and mesocortical dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597PubMedGoogle Scholar
- Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E (2006) Central serotonin2C receptor: from physiology to pathology. Curr Topics Med Chem 6:1909–1925Google Scholar
- Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson SJ (2005) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. Pharmacol Exp Ther 313:862–869Google Scholar
- Dutton AC, Barnes NM (2006) Anti-obesity pharmacotherapy: future perspectives utilising 5-HT2C receptor agonists. Drug Disc Today: Therapeutic Strategies 3:577–583Google Scholar
- File SE, Seth P (2003) A review of 25 years of the social interaction test. Eur J Pharm 463:35–53Google Scholar
- Gobert A, Rivet JP, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221PubMedGoogle Scholar
- Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E (2007) 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-b-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharm Exp Ther 320:1023–1029Google Scholar
- Invernizzi RW, Pieruci M, Calcagno E, Di Giovanni G, Di Matteo V, Benigno A, Esposito E (2007) Selective activation of the 5-HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144:1523–1535PubMedGoogle Scholar
- Kantor S, Jakus R, Molnar E, Gyongyosi N, Toth A, Detari L, Bagdy G (2005) Despite similar anxiolytic potential, the 5-HT2C receptor antagonist SB-242084 and chlordiazepoxide produced differential effects on EEG power spectra. J Pharm Exp Ther 315:921–930Google Scholar
- Kennett GA, Lightowler S, Trail B Bright F, Bromidge S (2000) Effects of RO 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur J Pharm 387:197–204Google Scholar
- Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486–496PubMedGoogle Scholar
- Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:53–244Google Scholar
- Millan MJ, Hjorth S, Samanin R, Schreiber R, Jaffard R, De Ladonchamps B, Veiga S, Goument B, Peglion JL, Spedding M, Brocco M (1997b) S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 282:148–161PubMedGoogle Scholar
- Millan MJ, Gobert A, Rivet J-M, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000a) Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of a2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12:1079–1095PubMedGoogle Scholar
- Millan MJ, Dekeyne A, Papp M, Drieu La Rochelle C, Macsweeny C, Peglion J-L, Brocco M (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharm Exp Ther 298:581–591Google Scholar
- Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-HT2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954–964PubMedGoogle Scholar
- Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 17:448–458Google Scholar
- Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M (2007) S33138, a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. III. Actions in models of therapeutic activity and induction of side-effects. J Pharmacol Exp Ther 324:1212–1226PubMedGoogle Scholar
- Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321:1054–1061PubMedGoogle Scholar
- Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology 192:159–70PubMedGoogle Scholar
- Sharma A, Punhani F, Fone KCF (1997) Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody effect of 5,7-dihydroxytryptamine. Synapse 26:45–56Google Scholar
- Van Veen JF, Van der Wee NJA, Fiselier J Van Vliet IM, Westenberg HGM (2007) Behavioural effects of rapid intravenous administration of meta-chlorophenyl piperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy control. Eur Neuropsychopharmacol 17:637–642PubMedGoogle Scholar
- Walker EA, Kohut SJ, Hass RW Brown EK, Prabandham A, Lefever T (2005) Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology 42:1210–1219Google Scholar
- Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199PubMedGoogle Scholar